PubMLST Database home Contents
Log in
Help

Full information on isolate 120M (id:2)

Projects

This isolate is a member of the following project:

107 global collection
This dataset was originally used to validate MLST and was chosen to represent global diversity of N. meningitidis in the latter half of the Twentieth Century. It has been used in many publications since and the isolates are available as the EMGM MLST reference collection.

Provenance/meta data

id
2
isolate
120M
aliases
B35; NIBSC_2822; Z1035
strain designation
A: P1.5-2,10: F5-1: ST-1 (cc1)
country
Pakistan
continent
Asia
year
1967
disease
meningitis and septicaemia
epidemiology
endemic
species
Neisseria meningitidis
serogroup
A
capsule group
A
MLEE designation
Subgroup I
serotype
4,21
sero subtype
P1.10
ET no
21
ENA accession
ERS007005 www.ebi.ac.uk
comments
Pili IIa,IIb
sender
Wendell Zollinger, Dept Bacterial Diseases,Walter Reed Army Institute of Research, Washington DC, USA
curator
Holly Bratcher, University of Oxford (E-mail: Holly.Bratcher@zoo.ox.ac.uk)
update history
115 updates show details
date entered
2001-02-07
datestamp
2019-01-01

Phenotypic data

Bexsero reactivity
cross-reactive  caveats
Trumenba reactivity
cross-reactive  caveats

Bexsero Antigen Sequence Typing (1) was developed to allow high-throughput analysis of whole genome sequence data and cataloguing of vaccine antigenic variants.

  • There are 5 components to the BAST: fHbp, NHBA, NadA, PorAVR1 and PorAVR2.
  • Only 4 are used in determining the likelihood of coverage by the Bexsero vaccine:fHbp, NHBA, NadA, and PorAVR2. Of these, only fHbp and NadA variants are considered potentially cross-reactive.
  • You can find the BAST antigenic profile for this isolate by selecting the Typing → Bexsero Antigen Sequence Typing (BAST) link in the scheme tree at the bottom of the page.
  • Bexsero contains: fHbp 1; NHBA: 2; NadA 8; PorA VR2: 4.

The traffic light system was devised to help users of the BAST system to determine the potential genomic coverage of a given isolate by Bexsero.

  • isolate contains exact antigenic variants found in the vaccine.
  • isolate contains cross-reactive antigenic variants.
  • isolate contains no antigenic variants that are either exact matches or cross-reactive to those found in the vaccine.

It is important to understand the caveats to the estimates made using genomic data as below:

  • These are genomic estimates of vaccine coverage based on the presence or absence of genes encoding vaccine antigenic variants.
  • We have not inferred the cross-reactivity of antigenic variants based on genomic data alone.
  • We have used published literature to obtain information about cross reactivity of the antigens, which demonstrates that vaccinee sera can directly kill meningococci in serum bactericidal antibody assays or through the Meningococcal Antigen Typing System (MATS) assay (2), an indirect measure of the potential to be killed by vaccinees’ sera.
  • We have not inferred protein expression from the genomic data, therefore there may be isolates that possess genes but do not express the protein in vivo.
  • The age of the vaccinees included in the published trials needs to be considered when interpreting potential coverage of an isolate with Bexsero or Trumenba, and deciding which vaccine to administer.

  1. Brehony et al. Vaccine 2016 34:4690-7
  2. Medini et al. Vaccine 2015 33:2629-36

Click to close

Trumenba is a bivalent fHbp-containing vaccine.

  • The vaccine contains fHbp protein variants 45 and 55.

The traffic light system was devised to help users of PubMLST to determine the potential genomic coverage of a given isolate by Trumenba.
  • isolate contains exact antigenic variants found in the vaccine.
  • isolate contains cross-reactive antigenic variants.
  • isolate contains no antigenic variants that are either exact matches or cross-reactive to those found in the vaccine.

It is important to understand the caveats to the estimates made using genomic data as below:

  • These are genomic estimates of vaccine coverage based on the presence or absence of genes encoding vaccine antigenic variants.
  • We have not inferred the cross-reactivity of antigenic variants based on genomic data alone.
  • We have used published literature to obtain information about cross reactivity of the antigens, which demonstrates that vaccinee sera can directly kill meningococci in serum bactericidal antibody assays or through the Meningococcal Antigen Typing System (MATS) assay (1), an indirect measure of the potential to be killed by vaccinees’ sera.
  • We have not inferred protein expression from the genomic data, therefore there may be isolates that possess genes but do not express the protein in vivo.
  • The age of the vaccinees included in the published trials needs to be considered when interpreting potential coverage of an isolate with Bexsero or Trumenba, and deciding which vaccine to administer.

  1. Medini et al. Vaccine 2015 33:2629-36

Click to close

Publications (9)

Sequence bin

contigs
359
total length
2,059,411 bp
max length
33,563 bp
mean length
5,737 bp
N50 contig number
60
N50 length (L50)
10,581
N90 contig number
200
N90 length (L90)
3,126
N95 contig number
241
N95 length (L95)
1,863
loci tagged
2,180
detailed breakdown
Display

Schemes and loci

Navigate and select schemes within tree to display allele designations

Tools

Analysis: